BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34710258)

  • 21. Low Rate of Cancer Events After Partial Nephrectomy for Renal Cell Carcinoma: Clinicopathologic Analysis of 1994 Cases with Emphasis on Definition of "Recurrence".
    Bertolo R; Nicolas M; Garisto J; Magi-Galluzzi C; McKenney JK; Kaouk J
    Clin Genitourin Cancer; 2019 Jun; 17(3):209-215.e1. PubMed ID: 31000486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA.
    Nizioł J; Bonifay V; Ossoliński K; Ossoliński T; Ossolińska A; Sunner J; Beech I; Arendowski A; Ruman T
    Anal Bioanal Chem; 2018 Jun; 410(16):3859-3869. PubMed ID: 29658093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma.
    Han WK; Alinani A; Wu CL; Michaelson D; Loda M; McGovern FJ; Thadhani R; Bonventre JV
    J Am Soc Nephrol; 2005 Apr; 16(4):1126-34. PubMed ID: 15744000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies.
    Abdelsalam ME; Sabir SH; Ba SBK; Karam JA; Matin SF; Wood CG; Ahrar K
    AJR Am J Roentgenol; 2021 Jul; 217(1):157-163. PubMed ID: 33909469
    [No Abstract]   [Full Text] [Related]  

  • 26. [Predicting postoperative recurrence of renal cell carcinoma using serum vascular endothelial growth factor].
    Fujita N; Okegawa T; Tambo M; Shishido T; Nutahara K; Higashihara E
    Nihon Hinyokika Gakkai Zasshi; 2013 Jan; 104(1):1-5. PubMed ID: 23457926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of urinary cell-free miR-210 as a potential tool of liquid biopsy for clear cell renal cell carcinoma.
    Li G; Zhao A; Péoch M; Cottier M; Mottet N
    Urol Oncol; 2017 May; 35(5):294-299. PubMed ID: 28089386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
    Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
    Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary Human Kidney Injury Molecule1- (hKIM1-) is not Increased in Patients with Renal Cell Carcinoma.
    Bialek L; Poletajew S; Niemczyk M; Czerwinska K; Nowak M; Sadowska A; Borkowski T; Radziszewski P; Dobruch J; Kryst P
    Urol J; 2020 Oct; 17(6):664-666. PubMed ID: 33000456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor size, stage and grade alterations of urinary peptidome in RCC.
    Chinello C; Cazzaniga M; De Sio G; Smith AJ; Grasso A; Rocco B; Signorini S; Grasso M; Bosari S; Zoppis I; Mauri G; Magni F
    J Transl Med; 2015 Oct; 13():332. PubMed ID: 26482227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma.
    Lee BH; Feifer A; Feuerstein MA; Benfante NE; Kou L; Yu C; Kattan MW; Russo P
    Eur Urol Focus; 2018 Jan; 4(1):100-105. PubMed ID: 28753780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of urinary glycosaminoglycan excretion in patients with renal cell carcinoma.
    Sarica K; Türkölmez K; Soygür T; Ozer G; Yaman MO; Baltaci S; Bedük Y; Müftüoğlu YZ
    Eur Urol; 1997; 31(1):54-7. PubMed ID: 9032535
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urinary aquaporin 1 and perilipin 2: Can these novel markers accurately characterize small renal masses and help guide patient management?
    Song JB; Morrissey JJ; Mobley JM; Figenshau KG; Vetter JM; Bhayani SB; Kharasch ED; Figenshau RS
    Int J Urol; 2019 Feb; 26(2):260-265. PubMed ID: 30467901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps.
    Zheng H; Ji J; Zhao L; Chen M; Shi A; Pan L; Huang Y; Zhang H; Dong B; Gao H
    Oncotarget; 2016 Sep; 7(37):59189-59198. PubMed ID: 27463020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microscopic venous invasion in renal cell carcinoma as a predictor of recurrence after radical surgery.
    Ishimura T; Sakai I; Hara I; Eto H; Miyake H
    Int J Urol; 2004 May; 11(5):264-8. PubMed ID: 15147540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of tumor histology and grade on treatment success of percutaneous renal cryoablation.
    Beksac AT; Rivera-Sanfeliz G; Dufour CA; Nseyo U; Hamilton Z; Berquist SW; Hassan AE; Raheem OA; Wang S; Wake RW; Gold RE; Derweesh IH
    World J Urol; 2017 Apr; 35(4):633-640. PubMed ID: 27484204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series.
    van der Mijn JC; Al Hussein Al Awamlh B; Islam Khan A; Posada-Calderon L; Oromendia C; Fainberg J; Alshak M; Elahjji R; Pierce H; Taylor B; Gudas LJ; Nanus DM; Molina AM; Del Pizzo J; Scherr DS
    PLoS One; 2019; 14(12):e0226285. PubMed ID: 31815952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncologic Surveillance After Surgical Resection for Renal Cell Carcinoma: A Novel Risk-Based Approach.
    Stewart-Merrill SB; Thompson RH; Boorjian SA; Psutka SP; Lohse CM; Cheville JC; Leibovich BC; Frank I
    J Clin Oncol; 2015 Dec; 33(35):4151-7. PubMed ID: 26351352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.